Shares of Merck and Pfizer are way down from their previous peaks. Merck's lead drug, Keytruda, grew sales by 19% last year, but its era of patent-protected exclusivity is approaching its end.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tesla's overall business has more dimensions to it than that of Archer. Beyond EVs, it also produces energy storage packs and is current investing heavily in artificial intelligence (AI) -- primarily ...

EST Cathie Wood’s ARK Investment bought 344K shares of PacBio (PACB) todayMaximize Your Portfolio with Data Driven Insights:Leverage the ...

It could get a whole lot harder to beat Cathie Wood's Ark Invest line of funds moving forward as artificial intelligence (AI) ...

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The president will today announce 25 percent tariffs on all steel and aluminum imports as his long-threatened global trade war heats up. Trump told reporters aboard Air Force One on Sunday afternoon ...

Ark Invest, led by Cathie Wood, sold a chunk of its Robinhood shares. The sales come after the company posted strong earnings ...

Stories about humanity for Inspired Life. Cathy Free is a former contributing editor for Reader's Digest and worked as a human interest correspondent for People Magazine before joining The Post.

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Merck & Co has said building its cardiovascular medicines business is central to its strategy to manage the loss of patent protection of cancer juggernaut Keytruda in five years, and new studies ...